AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00378092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-Acting Injection (RLAI)
Description: Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
Study NCT00785720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid)
Study NCT01081392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods
Study NCT00929721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: culture for Streptococcus pneumoniae Frequency-1
Study NCT00929721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest X-ray
Description: image of the lungs to assess changes consistent with pneumonia Frequency-1
Study NCT00929721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: urine specimen
Description: assay for the presence of Streptococcus pneumoniae Binax and UAD
Study NCT00929721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: culture for Streptococcus pneumoniae Frequency-1
Study NCT00929721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sputum
Description: culture for Streptococcus pneumoniae Frequency-1
Study NCT03414736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT04659551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg oral continuous daily dose until surgery
Study NCT04659551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
Study NCT01513135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tat
Description: Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
Study NCT01513135 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
Study NCT02373995 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LAB4
Description: Additional treatment with the specific LAB4 probiotic preparation
Study NCT01456741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBNA with ROSE
Description: The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Intramuscular injection
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection
Study NCT00786838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
Study NCT00786838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 3-hour placebo intravenous infusion on Day 1.
Study NCT06369675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: Topical formulation
Study NCT06369675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% SLS
Description: Positive control
Study NCT06369675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Saline
Description: Negative control
Study NCT06369675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B vehicle
Description: Topical formulation
Study NCT03013322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physostigmine
Study NCT03013322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Study NCT01839292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered D-type stent insertion
Study NCT01839292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double-layered ComVi stent insertion
Study NCT04020484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Mindfulness Matter© (M3)
Description: Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
Study NCT04020484 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Making Mindfulness Matter© (M3)
Description: Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
Study NCT01609803 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02410707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide arm
Description: Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
Study NCT02410707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
Study NCT02410707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
Study NCT03518099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
Study NCT02998554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
Study NCT02998554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Study NCT01274442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anamnesis
Description: To update the anamnesis.
Study NCT01274442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anamnesis
Description: To update the anamnesis.
Study NCT01274442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral examination
Description: A brief clinical oral examination will be performed.
Study NCT01274442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral examination
Description: A brief clinical oral examination will be performed.
Study NCT04028635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
Study NCT04028635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Usual CBT
Study NCT02839369 — intervention group
Intervention type: OTHER
Intervention: walking under varies conditions
Description: The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
Study NCT01456741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard EBNA
Description: The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD1775 Placebo
Description: Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimitotic Agent
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antimitotic Agent
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfiligrastim
Description: Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Study NCT02087176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegfiligrastim
Description: Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Study NCT02839369 — intervention group
Intervention type: OTHER
Intervention: walking under varies conditions
Description: walking on electronic walkway under different conditions
Study NCT01918579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be tested by rapid POC CRP test
Description: Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
Study NCT02244294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOMAX® capsules
Study NCT02244294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT03192046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Ankle Foot Orthosis (AFO)
Description: Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
Study NCT03192046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized walking/exercise program
Description: standardized walking/exercise program without any brace or AFO
Study NCT04577625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri (L. reuteri)
Description: L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
Study NCT02439632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prulifloxacin
Study NCT02439632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
Study NCT02439632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prulifloxacin Placebo
Description: Placebo of prulifloxacin film-coated tablet without active components.
Study NCT02439632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Placebo
Description: Placebo of levofloxacin hydrochloride tablet without active components.
Study NCT01674439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplementation of ADRC
Description: Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
Study NCT01674439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without supplementation of ADRC
Description: Standard fat graft preparation
Study NCT02792348 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis on urine sample
Description: Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
Study NCT00688428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg/ASA 325mg
Description: combination capsule, administered as a single oral dose
Study NCT00688428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg capsule, administered as a single dose
Study NCT00688428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 325mg tablet, administered as a single oral dose
Study NCT04788446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-flipped Game-based Learning
Description: The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
Study NCT04577625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri (L. reuteri)
Description: L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
Study NCT04788446 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Balanced diet
Description: Given a balanced diet nutrition health education manual for the aged.
Study NCT03588052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA using PRF
Description: Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured
Study NCT03588052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VISTA using SCTG
Description: Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured
Study NCT02651142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients receive SLNB
Description: Patients receive sentinel lymph node biopsy
Study NCT02916836 — intervention group
Intervention type: OTHER
Intervention: therapeutic drug conciliation sheet (TDC)
Description: Use of therapeutic drug conciliation sheet (TDC)
Study NCT02916836 — intervention group
Intervention type: OTHER
Intervention: No Use of therapeutic drug conciliation sheet (TDC)
Study NCT00031512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study NCT00031512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleconaril
Description: 5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
Study NCT02500654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain®
Description: Surgery and Emdogain®
Study NCT02500654 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery alone
Description: Surgery alone
Study NCT02967588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients.
Study NCT03884244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: The group who take chewing gum after operation
Study NCT02297880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing low calorie sweeteners
Description: Beverage containing low calorie sweeteners
Study NCT02297880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Still water
Description: Still water (no flavour)
Study NCT00754936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg by mouth daily
Study NCT04696341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matrix Rhythm Therapy
Description: Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.